A3. The use of micro-array analyses in the adjuvant setting for breast cancer?  by unknown
A3. THE USE OF MICROARRAY ANALYSES IN THE ADJUVANT
SETTING FOR BREAST CANCER
Marc J van de Vijver. Department of Pathology, Netherlands Cancer Institute,
Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
In the treatment of breast cancer, patient-tailored therapy is becoming
increasingly important. Decisions on optimal treatment include the choice
between mastectomy and breast-conserving treatment; dose of radiotherapy; and
decisions on adjuvant chemotherapy and hormonal therapy.
Gene expression proﬁling by micro-array analysis allows the study of the level of
expression of large numbers of mRNA’s in a single experiment. Gene expression
analysis can be used to subclassify tumours on the basis of hierarchical cluster
analysis in speciﬁc subgroups; supervised cluster analysis can be used to directly
link gene expression proﬁles to clinical characteristics, including prognosis and
response to various forms of treatment.
We have used micro-array analysis, ﬁrst on a series of 117 breast carcinomas
and, more recently, on a series of 295 breast carcinomas.
We have deﬁned a gene expression proﬁle of 70 genes that is predictive for a
short interval to distant metastases (<5 years) in lymph node-negative (LN0)
patients. We have validated the prognostic value of this gene expression proﬁle
in lymph node-negative patients; and also in premenopausal lymph node-
positive patients. The proﬁle outperforms all currently used clinical parameters
in predicting outcome of disease.
At present, we are exploring the possibilities to use the prognostic expression
proﬁle in guiding adjuvant systemic treatment in lymph node-negative breast
cancer patients younger than 60 years.
doi:10.1016/j.ejcsup.2004.08.026
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In early breast cancer, all clinically apparent disease can be removed
surgically. Following such surgery, adjuvant systemic treatments involving
various cytotoxic, hormonal or other therapies may be considered. Before the
1980’s, despite many trials of diﬀerent adjuvant therapies, there was
substantial uncertainty as to the net eﬀects of such treatments, particularly
on survival, because none of the trials was large enough individually to
provide reliable answers. In 1983, the Clinical Trail Service Unit (CTSU)
established the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
to bring together updated data on each woman randomised into all trials on
the treatment of early breast cancer, in an overview or series of systematic
reviews. These reviews provide deﬁnitive evidence on the eﬀects of treatments
on recurrence, second cancer and mortality, which could not be obtained by
other means. The fourth cycle of data collection (involving 200 000 women in
400 randomised trials, done by 250 trial groups) was presented to the
EBCTCG for discussion in September 2000. Analyses were available for
10 000 women who were randomised in trials directly comparing diﬀerent
types of surgery; 10 000 in trials of ovarian ablation or suppression; 20 000 in
trials of radiotherapy; 50 000 in trials of chemotherapy (including trials of
chemotherapy versus control and direct comparisons of diﬀerent regimens)
and 80 000 in trials of tamoxifen (50 000 in trials of tamoxifen versus control,
and 30 000 in trials of diﬀerent durations of tamoxifen). The main results
will be presented.
doi:10.1016/j.ejcsup.2004.08.028
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